InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
1.215
+0.025 (2.10%)
Mar 17, 2025, 2:33 PM EDT - Market open
InflaRx Employees
InflaRx had 62 employees as of December 31, 2023. The number of employees increased by 18 or 40.41% compared to the previous year.
Employees
62
Change (1Y)
18
Growth (1Y)
40.41%
Revenue / Employee
$3,021
Profits / Employee
-$1,019,980
Market Cap
71.54M
Employees Chart
IFRX News
- 10 days ago - InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - GlobeNewsWire
- 17 days ago - InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - GlobeNewsWire
- 20 days ago - InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences - GlobeNewsWire
- 26 days ago - InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 4 weeks ago - InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 4 weeks ago - InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 7 weeks ago - InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 2 months ago - InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) - GlobeNewsWire